Purpose: To assess the comparative effectiveness and safety of dabigatran‒globally and
strati ed by dose (110 or 150 mg bid) compared to vitamin K antagonists (VKA) in patients …

Abstract Background and Objective Real-life data about the use of dabigatran in patients
with non-valvular atrial fibrillation are warranted. The objective of this systematic review and …

Background: In the clinical trial RE-LY, dabigatran showed a better efficacy/safety profile in
comparison with warfarin, but clinical trials are few representative of the real world. We aim …

Background Prospectively collected, routine clinical practice-based data on antithrombotic
therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world …

In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …

Large randomized controlled trials have found that in non-valvular atrial fibrillation (AF), non-
vitamin K antagonist oral anticoagulants (NOACs) had a favorable risk–benefit profile, with …

Background The recent availability of dabigatran, a novel oral anticoagulant, provided a new
treatment option for stroke prevention in atrial fibrillation beyond warfarin, the main therapy …

Introduction: Nonvalvular atrial fibrillation (NVAF) is associated with a fivefold excess risk of
stroke. Antithrombotic therapy is crucial to reduce the risk of stroke. During past decades …

Background: Dabigatran is a novel oral anticoagulant approved recently for stroke
prevention in atrial fibrillation (AF) in North America. We aimed to assess the effectiveness …

Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs), with
a non-inferior or superior clinical efficacy profile compared to vitamin K antagonists (VKAs) …